1. Home
  2. NHS vs OBIO Comparison

NHS vs OBIO Comparison

Compare NHS & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neuberger Berman High Yield Strategies Fund

NHS

Neuberger Berman High Yield Strategies Fund

HOLD

Current Price

$6.14

Market Cap

259.9M

Sector

Finance

ML Signal

HOLD

Logo Orchestra BioMed Holdings Inc.

OBIO

Orchestra BioMed Holdings Inc.

HOLD

Current Price

$3.70

Market Cap

238.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NHS
OBIO
Founded
2003
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
259.9M
238.9M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
NHS
OBIO
Price
$6.14
$3.70
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$14.25
AVG Volume (30 Days)
237.0K
521.0K
Earning Date
01-01-0001
05-11-2026
Dividend Yield
13.44%
N/A
EPS Growth
N/A
33.13
EPS
N/A
N/A
Revenue
N/A
$33,482,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$12.43
P/E Ratio
N/A
N/A
Revenue Growth
N/A
1169.22
52 Week Low
$6.06
$2.20
52 Week High
$7.75
$5.42

Technical Indicators

Market Signals
Indicator
NHS
OBIO
Relative Strength Index (RSI) 39.35 40.63
Support Level $6.06 $3.47
Resistance Level $6.30 $4.18
Average True Range (ATR) 0.06 0.26
MACD 0.00 -0.05
Stochastic Oscillator 7.83 7.58

Price Performance

Historical Comparison
NHS
OBIO

About NHS Neuberger Berman High Yield Strategies Fund

Neuberger Berman High Yield Strategies Fund Inc is a diversified, closed-end management investment company. The company invests in high yield debt securities market. The Fund uses leverage to pursue its investment objective. The Fund may invest in a variety of direct debt instruments, including bank loans, notes and other interests in amounts owed to financial institutions by borrowers, such as companies and governments. Corporate loans in which the Fund may invest will consist of direct obligations of borrowers. The Fund may invest in corporate loans at origination as a co-lender or may acquire loans in the secondary market by purchasing participations in, assignments of or novations of corporate loans.

About OBIO Orchestra BioMed Holdings Inc.

Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.

Share on Social Networks: